The tetherin antagonism of the Ebola virus glycoprotein requires an intact receptor-binding domain and can be blocked by GP1-specific antibodies

Journal of Virology

Volumn 90, Issue 24, 2016, Pages 11075-11086

  Brinkmann, Constantin ^a   Nehlmeier, Inga ^a   Walendy Gnirß, Kerstin ^a,f   Nehls, Julia ^b,c   Hernández, Mariana González ^a   Hoffmann, Markus ^a   Qiu, Xiangguo ^d   Takada, Ayato ^e   Schindler, Michael ^b,c   Pöhlmann, Stefan ^a  

^a GERMAN PRIMATE CENTER   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^e HOKKAIDO UNIVERSITY   (Japan)

^f LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIVIRUS AGENT; BINDING PROTEIN; GLYCAN; NPC1 PROTEIN; TETHERIN; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS GLYCOPROTEIN; BST2 PROTEIN, HUMAN; GLYCOPROTEIN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; LEUKOCYTE ANTIGEN; NEUTRALIZING ANTIBODY; POLYSACCHARIDE; PROTEIN BINDING; PROTEIN SUBUNIT; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EBOLAVIRUS; EMBRYO; FILOVIRUS; HUMAN; HUMAN CELL; LLOVIU VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SUBUNIT; RECEPTOR BINDING; AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; HOST PATHOGEN INTERACTION; IMMUNOLOGY; METABOLISM; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; VIRUS ENTRY; VIRUS RELEASE; VIRUS REPLICATION;

AMINO ACID SEQUENCE; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, CD; EBOLAVIRUS; GENE EXPRESSION REGULATION; GLYCOPROTEINS; GPI-LINKED PROTEINS; HEK293 CELLS; HOST-PATHOGEN INTERACTIONS; HUMANS; POLYSACCHARIDES; PROTEIN BINDING; PROTEIN DOMAINS; PROTEIN SUBUNITS; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; VIRAL ENVELOPE PROTEINS; VIRUS INTERNALIZATION; VIRUS RELEASE; VIRUS REPLICATION;

EID: 85000910582     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01563-16     Document Type: Article

References (66)

1. Ebola Response Team WHO. 2016. Ebola virus disease among male and female persons in West Africa. N Engl J Med 374:96-98. http://dx.doi.org /10.1056/NEJMc1510305.
2. WHO. 17 February 2016. Ebola situation report-17 February 2016. http: //apps.who.int/ebola/current-situation/ebola-situation-report-17-february-2016.
3. Basler CF. 2015. Innate immune evasion by filoviruses. Virology 479-480: 122-130. http://dx.doi.org/10.1016/j.virol.2015.03.030.
4. Misasi J, Sullivan NJ. 2014. Camouflage and misdirection: the full-on assault of ebola virus disease. Cell 159:477-486. http://dx.doi.org/10.1016 /j.cell.2014.10.006.
5. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, Rice CM. 2011. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472:481-485. http://dx.doi.org/10.1038/nature09907.
6. Neil SJ, Zang T, Bieniasz PD. 2008. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451:425-430. http://dx.doi.org /10.1038/nature06553.
7. Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, Johnson MC, Stephens EB, Guatelli J. 2008. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3:245-252. http://dx.doi.org /10.1016/j.chom.2008.03.001.
8. Perez-Caballero D, Zang T, Ebrahimi A, McNatt MW, Gregory DA, Johnson MC, Bieniasz PD. 2009. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 139:499-511. http://dx.doi.org/10.1016/j.cell.2009.08.039.
9. Neil SJ. 2013. The antiviral activities of tetherin. Curr Top Microbiol Immunol 371:67-104. http://dx.doi.org/10.1007/978-3-642-37765-5_3.
10. McNatt MW, Zang T, Bieniasz PD. 2013. Vpu binds directly to tetherin and displaces it from nascent virions. PLoS Pathog 9:e1003299. http://dx.doi.org/10.1371/journal.ppat.1003299.
11. Iwabu Y, Fujita H, Kinomoto M, Kaneko K, Ishizaka Y, Tanaka Y, Sata T, Tokunaga K. 2009. HIV-1 accessory protein Vpu internalizes cellsurface BST-2/tetherin through transmembrane interactions leading to lysosomes. J Biol Chem 284:35060-35072. http://dx.doi.org/10.1074/jbc.M109.058305.
12. Vigan R, Neil SJ. 2010. Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein. J Virol 84:12958-12970. http://dx.doi.org/10.1128/JVI.01699-10.
13. Banning C, Votteler J, Hoffmann D, Koppensteiner H, Warmer M, Reimer R, Kirchhoff F, Schubert U, Hauber J, Schindler M. 2010. A flow cytometry-based FRET assay to identify and analyse protein-protein interactions in living cells. PLoS One 5:e9344. http://dx.doi.org/10.1371 /journal.pone.0009344.
14. Douglas JL, Viswanathan K, McCarroll MN, Gustin JK, Fruh K, Moses AV. 2009. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a (beta)TrCPdependent mechanism. J Virol 83:7931-7947. http://dx.doi.org/10.1128/JVI.00242-09.
15. Mangeat B, Gers-Huber G, Lehmann M, Zufferey M, Luban J, Piguet V. 2009 HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog 5:e1000574. http://dx.doi.org/10.1371/journal.ppat.1000574.
16. Mitchell RS, Katsura C, Skasko MA, Fitzpatrick K, Lau D, Ruiz A, Stephens EB, Margottin-Goguet F, Benarous R, Guatelli JC. 2009. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking. PLoS Pathog 5:e1000450. http://dx.doi.org/10.1371/journal.ppat.1000450.
17. Carette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, Mulherkar N, Kuehne AI, Kranzusch PJ, Griffin AM, Ruthel G, Dal CP, Dye JM, Whelan SP, Chandran K, Brummelkamp TR. 2011. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 477: 340-343. http://dx.doi.org/10.1038/nature10348.
18. Cote M, Misasi J, Ren T, Bruchez A, Lee K, Filone CM, Hensley L, Li Q, Ory D, Chandran K, Cunningham J. 2011. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 477: 344-348. http://dx.doi.org/10.1038/nature10380.
19. Kaletsky RL, Francica JR, Agrawal-Gamse C, Bates P. 2009. Tetherinmediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sci U S A 106:2886-2891. http://dx.doi.org/10.1073/pnas.0811014106.
20. Kühl A, Banning C, Marzi A, Votteler J, Steffen I, Bertram S, Glowacka I, Konrad A, Sturzl M, Guo JT, Schubert U, Feldmann H, Behrens G, Schindler M, Pöhlmann S. 2011. The Ebola virus glycoprotein and HIV-1 Vpu employ different strategies to counteract the antiviral factor tetherin. J Infect Dis 204:S850-S860. http://dx.doi.org/10.1093/infdis/jir378.
21. Lopez LA, Yang SJ, Hauser H, Exline CM, Haworth KG, Oldenburg J, Cannon PM. 2010. Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal. J Virol 84:7243-7255. http://dx.doi.org/10.1128/JVI.02636-09.
22. Lopez LA, Yang SJ, Exline CM, Rengarajan S, Haworth KG, Cannon PM. 2012. Anti-tetherin activities of HIV-1 Vpu and Ebola virus glycoprotein do not involve removal of tetherin from lipid rafts. J Virol 86: 5467-5480. http://dx.doi.org/10.1128/JVI.06280-11.
23. Gustin JK, Bai Y, Moses AV, Douglas JL. 2015. Ebola virus glycoprotein promotes enhanced viral egress by preventing Ebola VP40 from associating with the host restriction factor BST2/tetherin. J Infect Dis 212(Suppl 2):S181-S190. http://dx.doi.org/10.1093/infdis/jiv125.
24. Martinez O, Leung LW, Basler CF. 2012. The role of antigen-presenting cells in filoviral hemorrhagic fever: gaps in current knowledge. Antiviral Res 93:416-428. http://dx.doi.org/10.1016/j.antiviral.2012.01.011.
25. Schindler M, Rajan D, Banning C, Wimmer P, Koppensteiner H, Iwanski A, Specht A, Sauter D, Dobner T, Kirchhoff F. 2010. Vpu serine 52 dependent counteraction of tetherin is required for HIV-1 replication in macrophages, but not in ex vivo human lymphoid tissue. Retrovirology 7:1. http://dx.doi.org/10.1186/1742-4690-7-1.
26. Wrensch F, Karsten CB, Gnirss K, Hoffmann M, Lu K, Takada A, Winkler M, Simmons G, Pöhlmann S. 2015. Interferon-induced transmembrane protein-mediated inhibition of host cell entry of ebolaviruses. J Infect Dis 212(Suppl 2):S210-S218. http://dx.doi.org/10.1093/infdis /jiv255.
27. Negredo A, Palacios G, Vazquez-Moron S, Gonzalez F, Dopazo H, Molero F, Juste J, Quetglas J, Savji N, de la Cruz MM, Herrera JE, Pizarro M, Hutchison SK, Echevarria JE, Lipkin WI, Tenorio A. 2011. Discovery of an ebolavirus-like filovirus in Europe. PLoS Pathog 7:e1002304. http://dx.doi.org/10.1371/journal.ppat.1002304.
28. Gnirss K, Fiedler M, Kramer-Kuhl A, Bolduan S, Mittler E, Becker S, Schindler M, Pöhlmann S. 2014. Analysis of determinants in filovirus glycoproteins required for tetherin antagonism. Viruses 6:1654-1671. http://dx.doi.org/10.3390/v6041654.
29. Vande Burgt NH, Kaletsky RL, Bates P. 2015. Requirements within the Ebola viral glycoprotein for tetherin antagonism. Viruses 7:5587-5602. http://dx.doi.org/10.3390/v7102888.
30. Reeves PJ, Callewaert N, Contreras R, Khorana HG. 2002. Structure and function in rhodopsin: high-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible Nacetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line. Proc Natl Acad Sci U S A 99:13419-13424. http://dx.doi.org/10.1073 /pnas.212519299.
31. Sauter D, Schindler M, Specht A, Landford WN, Munch J, Kim KA, Votteler J, Schubert U, Bibollet-Ruche F, Keele BF, Takehisa J, Ogando Y, Ochsenbauer C, Kappes JC, Ayouba A, Peeters M, Learn GH, Shaw G, Sharp PM, Bieniasz P, Hahn BH, Hatziioannou T, Kirchhoff F. 2009. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 6:409-421 http://dx.doi.org/10.1016/j.chom.2009.10.004.
32. Martinez O, Ndungo E, Tantral L, Miller EH, Leung LW, Chandran K, Basler CF. 2013. A mutation in the Ebola virus envelope glycoprotein restricts viral entry in a host species-and cell-type-specific manner. J Virol 87:3324-3334. http://dx.doi.org/10.1128/JVI.01598-12.
33. Marzi A, Akhavan A, Simmons G, Gramberg T, Hofmann H, Bates P, Lingappa VR, Pöhlmann S. 2006. The signal peptide of the ebolavirus glycoprotein influences interaction with the cellular lectins DCSIGN and DC-SIGNR. J Virol 80:6305-6317. http://dx.doi.org/10.1128/JVI.02545-05.
34. Reference deleted.
35. Maruyama J, Miyamoto H, Kajihara M, Ogawa H, Maeda K, Sakoda Y, Yoshida R, Takada A. 2014. Characterization of the envelope glycoprotein of a novel filovirus, lloviu virus. J Virol 88:99-109. http://dx.doi.org /10.1128/JVI.02265-13.
36. Wrensch F, Winkler M, Pöhlmann S. 2014. IFITM proteins inhibit entry driven by the MERS-coronavirus spike protein: evidence for cholesterolindependent mechanisms. Viruses 6:3683-3698. http://dx.doi.org/10.3390/v6093683.
37. Martin-Serrano J, Zang T, Bieniasz PD. 2001. HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nat Med 7:1313-1319. http://dx.doi.org/10.1038 /nm1201-1313.
38. Qiu X, Alimonti JB, Melito PL, Fernando L, Stroher U, Jones SM. 2011. Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. Clin Immunol 141:218-227. http://dx.doi.org/10.1016/j.clim.2011.08.008.
39. Qiu X, Fernando L, Melito PL, Audet J, Feldmann H, Kobinger G, Alimonti JB, Jones SM. 2012. Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection. PLoS Negl Trop Dis 6:e1575. http://dx.doi.org/10.1371/journal.pntd.0001575.
40. Gorny MK, Gianakakos V, Sharpe S, Zolla-Pazner S. 1989. Generation of human monoclonal antibodies to human immunodeficiency virus. Proc Natl Acad Sci U S A 86:1624-1628. http://dx.doi.org/10.1073/pnas.86.5.1624.
41. Marzi A, Wegele A, Pöhlmann S. 2006. Modulation of virion incorporation of Ebolavirus glycoprotein: effects on attachment, cellular entry and neutralization. Virology 352:345-356. http://dx.doi.org/10.1016/j.virol.2006.04.038.
42. Shoemaker CJ, Schornberg KL, Delos SE, Scully C, Pajouhesh H, Olinger GG, Johansen LM, White JM. 2013. Multiple cationic amphiphiles induce a Niemann-PickCphenotype and inhibit Ebola virus entry and infection. PLoS One 8:e56265. http://dx.doi.org/10.1371/journal.pone.0056265.
43. Hoffmann M, Gonzalez HM, Berger E, Marzi A, Pöhlmann S. 2016. The glycoproteins of all filovirus species use the same host factors for entry into bat and human cells but entry efficiency is species dependent. PLoS One 11:e0149651. http://dx.doi.org/10.1371/journal.pone.0149651.
44. Berger Rentsch M, Zimmer G. 2011. A vesicular stomatitis virus replicon-based bioassay for the rapid and sensitive determination of multispecies type I interferon. PLoS One 6:e25858. http://dx.doi.org/10.1371 /journal.pone.0025858.
45. Hoffmann M, Muller MA, Drexler JF, Glende J, Erdt M, Gutzkow T, Losemann C, Binger T, Deng H, Schwegmann-Wessels C, Esser KH, Drosten C, Herrler G. 2013. Differential sensitivity of bat cells to infection by enveloped RNA viruses: coronaviruses, paramyxoviruses, filoviruses, and influenza viruses. PLoS One 8:e72942. http://dx.doi.org/10.1371 /journal.pone.0072942.
46. Schneider CA, Rasband WS, Eliceiri KW. 2012. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9:671-675. http://dx.doi.org/10.1038/nmeth.2089.
47. Hagen N, Bayer K, Rosch K, Schindler M. 2014. The intraviral protein interaction network of hepatitis C virus. Mol Cell Proteomics 13:1676-1689 http://dx.doi.org/10.1074/mcp.M113.036301.
48. Medina MF, Kobinger GP, Rux J, Gasmi M, Looney DJ, Bates P, Wilson JM. 2003. Lentiviral vectors pseudotyped with minimal filovirus envelopes increased gene transfer in murine lung. Mol Ther 8:777-789. http: //dx.doi.org/10.1016/j.ymthe.2003.07.003.
49. Reference deleted.
50. Manicassamy B, Wang J, Jiang H, Rong L. 2005. Comprehensive analysis of ebola virus GP1 in viral entry. J Virol 79:4793-4805. http://dx.doi.org /10.1128/JVI.79.8.4793-4805.2005.
51. Markosyan RM, Miao C, Zheng YM, Melikyan GB, Liu SL, Cohen FS. 2016. Induction of cell-cell fusion by Ebola virus glycoprotein: low pH is not a trigger. PLoS Pathog 12:e1005373. http://dx.doi.org/10.1371/journal.ppat.1005373.
52. Cenedella RJ. 2009. Cholesterol synthesis inhibitor U18666A and the role of sterol metabolism and trafficking in numerous pathophysiological processes. Lipids 44:477-487. http://dx.doi.org/10.1007/s11745-009-3305-7.
53. Lu F, Liang Q, Abi-Mosleh L, Das A, De Brabander JK, Goldstein JL, Brown MS. 2015. Identification of NPC1 as the target of U18666A, an inhibitor of lysosomal cholesterol export and Ebola infection. eLife 4:e12177. http://dx.doi.org/10.7554/eLife.12177.
54. Coleman CM, Spearman P, Wu L. 2011. Tetherin does not significantly restrict dendritic cell-mediated HIV-1 transmission and its expression is upregulated by newly synthesized HIV-1 Nef. Retrovirology 8:26. http: //dx.doi.org/10.1186/1742-4690-8-26.
55. Geisbert TW, Hensley LE, Larsen T, Young HA, Reed DS, Geisbert JB, Scott DP, Kagan E, Jahrling PB, Davis KJ. 2003. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 163:2347-2370. http://dx.doi.org/10.1016/S0002-9440(10)63591-2.
56. Ryabchikova EI, Kolesnikova LV, Luchko SV. 1999. An analysis of features of pathogenesis in two animal models of Ebola virus infection. J Infect Dis 179(Suppl 1):S199-S202. http://dx.doi.org/10.1086/514293.
57. Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, Saphire EO. 2008 Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454:177-182. http://dx.doi.org/10.1038/nature07082.
58. Jeffers SA, Sanders DA, Sanchez A. 2002. Covalent modifications of the ebola virus glycoprotein. J Virol 76:12463-12472. http://dx.doi.org/10.1128/JVI.76.24.12463-12472.2002.
59. Lennemann NJ, Rhein BA, Ndungo E, Chandran K, Qiu X, Maury W. 2014 Comprehensive functional analysis of N-linked glycans on Ebola virus GP1. mBio 5:e00862-13.
60. Lin G, Simmons G, Pöhlmann S, Baribaud F, Ni H, Leslie GJ, Haggarty BS, Bates P, Weissman D, Hoxie JA, Doms RW. 2003. Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR. J Virol 77:1337-1346. http://dx.doi.org/10.1128/JVI.77.2.1337-1346.2003.
61. Brindley MA, Hughes L, Ruiz A, McCray PB, Jr, Sanchez A, Sanders DA, Maury W. 2007. Ebola virus glycoprotein 1: identification of residues important for binding and postbinding events. J Virol 81:7702-7709. http: //dx.doi.org/10.1128/JVI.02433-06.
62. Kuhn JH, Radoshitzky SR, Guth AC, Warfield KL, Li W, Vincent MJ, Towner JS, Nichol ST, Bavari S, Choe H, Aman MJ, Farzan M. 2006. Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor. J Biol Chem 281:15951-15958. http://dx.doi.org/10.1074/jbc.M601796200.
63. Wang H, Shi Y, Song J, Qi J, Lu G, Yan J, Gao GF. 2016. Ebola viral glycoprotein bound to its endosomal receptor Niemann-Pick C1. Cell 164:258-268. http://dx.doi.org/10.1016/j.cell.2015.12.044.
64. Dube D, Schornberg KL, Stantchev TS, Bonaparte MI, Delos SE, Bouton AH, Broder CC, White JM. 2008. Cell adhesion promotes Ebola virus envelope glycoprotein-mediated binding and infection. J Virol 82: 7238-7242. http://dx.doi.org/10.1128/JVI.00425-08.
65. Dube D, Schornberg KL, Shoemaker CJ, Delos SE, Stantchev TS, Clouse KA, Broder CC, White JM. 2010. Cell adhesion-dependent membrane trafficking of a binding partner for the ebolavirus glycoprotein is a determinant of viral entry. Proc Natl Acad Sci U S A 107:16637-16642. http://dx.doi.org/10.1073/pnas.1008509107.
66. Zhao Y, Ren J, Harlos K, Jones DM, Zeltina A, Bowden TA, Padilla-Parra S, Fry EE, Stuart DI. 2016. Toremifene interacts with and destabilizes the Ebola virus glycoprotein. Nature 535:169-172. http://dx.doi.org/10.1038/nature18615.